The 4 Wall Street analysts covering Shoulder Innovations, Inc. hold a median 12-month price target of $23 — +2.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 24 of 100 as at 1 Aug 2026 — in the weakest quartile.
Consensus tells you what everyone already believes. The model scores Shoulder Innovations, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (70): Analysts have, on balance, been raising their forecasts.
Accruals (26): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
The rank is the raw material. Whether the rules would actually own Shoulder Innovations, Inc. — and when they’d sell — is the membership.
The bullish and bearish analyst opinions on SI, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +2.8% from it.
Of the 20 most recent actions, 1 moved their price target up and 8 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 28 July 2026 | UBS | Initiates | Buy | $27 |
| 8 May 2026 | Piper Sandler | Reiterates | Overweight | $18 → $19 |
| 11 Mar 2026 | BTIG | Maintains | Buy | — |
| 2 Dec 2025 | Morgan Stanley | Maintains | Overweight | — |
| 12 Nov 2025 | Piper Sandler | Reiterates | Overweight | — |
| 9 Sept 2025 | BTIG | Reiterates | Buy | — |
| 26 Aug 2025 | Morgan Stanley | Initiates | Overweight | — |
| 25 Aug 2025 | Goldman Sachs | Initiates | Buy | — |
| 25 Aug 2025 | Jefferies | Initiates | Buy | — |
| 25 Aug 2025 | Piper Sandler | Initiates | Overweight | — |
| 6 Mar 2023 | Wedbush | Downgrade | Underperform | $4.00 |
| 2 Mar 2023 | Canaccord Genuity | Downgrade | Hold | $25 → $9.00 |
| 2 Mar 2023 | JP Morgan | Downgrade | Underweight | — |
| 1 Mar 2023 | Keefe, Bruyette & Woods | Downgrade | Market Perform | $25 → $16 |
| 9 Jan 2023 | Goldman Sachs | Maintains | Neutral | $35 → $10 |
| 9 Jan 2023 | Morgan Stanley | Maintains | Underweight | $24 → $13 |
| 9 Jan 2023 | Wedbush | Downgrade | Neutral | $15 → $9.00 |
| 6 Jan 2023 | B of A Securities | Downgrade | Underperform | $37 → $8.00 |
| 6 Jan 2023 | BTIG | Maintains | Buy | $51 → $21 |
| 6 Jan 2023 | Canaccord Genuity | Maintains | Buy | $150 → $25 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 90% of US stocks
Cheaper than 14% of US stocks
Cheaper than 29% of US stocks
Cheaper than 89% of US stocks
Higher than 66% of US stocks
Higher than 81% of US stocks
Higher than 89% of US stocks
Higher than 15% of US stocks
Higher than 98% of US stocks
Higher than 27% of US stocks
Higher than 17% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SI appears on the weeks it earns a place.
Shoulder Innovations announced that members of its management team will present at the Canaccord Genuity 46th Annual Growth Conference.
Why it matters — Presenting at a growth conference increases the company's visibility among potential investors and industry analysts.
The 4 Wall Street analysts covering Shoulder Innovations, Inc. have a median 12-month price target of $23, with estimates ranging from $19 to $27. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 4 analysts covering Shoulder Innovations, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Shoulder Innovations, Inc. 24 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 1 Aug 2026, Shoulder Innovations, Inc. ranks 24 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (70 of 100).
No one can know that. What the data says: the median 12-month target from 4 analysts implies +2.8% from the last close, and Ticker Nerd's factor model ranks Shoulder Innovations, Inc. 24 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Shoulder Innovations, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $19 to $27 over the next 12 months.
Shoulder Innovations, Inc. returned +57.1% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Shoulder Innovations, Inc. is a medical technology company that designs, develops, manufactures, and distributes implant replacement systems for shoulder arthroplasty in the United States.
The most recent item we track (PRNewsWire, 29 July 2026): "Shoulder Innovations to Participate in the Canaccord Genuity 46th Annual Growth Conference". Shoulder Innovations announced that members of its management team will present at the Canaccord Genuity 46th Annual Growth Conference.
Shoulder Innovations, Inc. is a medical technology company that designs, develops, manufactures, and distributes implant replacement systems for shoulder arthroplasty in the United States. The company focuses on transforming the shoulder surgical care market by providing advanced shoulder implant solutions and related technologies that support preoperative planning, implant selection, and procedural efficiency. Shoulder Innovations’ portfolio centers on its InSet Glenoid and other implant systems, engineered to enhance fixation, reduce mechanical stress at the bone-implant interface, and improve stability in shoulder joint reconstruction. These products are used by orthopedic surgeons to treat patients requiring shoulder replacement due to degenerative conditions, trauma, or other pathologies. Operating as a commercial-stage enterprise, Shoulder Innovations serves hospitals and surgical centers through specialized sales channels and clinical relationships. Founded in 2009 and headquartered in Grand Rapids, Michigan, the company plays a specialized role within the orthopedic and broader medical device market by concentrating exclusively on shoulder-focused solutions.
CEO Mr. Robert Ball · 56 employees · United States · https://www.shoulderinnovations.com